Literature DB >> 21574998

Lysosomal accumulation of Trk protein in brain of GM₁ -gangliosidosis mouse and its restoration by chemical chaperone.

Ayumi Takamura1, Katsumi Higaki, Haruaki Ninomiya, Tomoko Takai, Junichiro Matsuda, Masami Iida, Kousaku Ohno, Yoshiyuki Suzuki, Eiji Nanba.   

Abstract

G(M1) -gangliosidosis is a fatal neurodegenerative disorder caused by deficiency of lysosomal acid β-galactosidase (β-gal). Accumulation of its substrate ganglioside G(M1) (G(M1) ) in lysosomes and other parts of the cell leads to progressive neurodegeneration, but underlying mechanisms remain unclear. Previous studies demonstrated an essential role for interaction of G(M1) with tropomyosin receptor kinase (Trk) receptors in neuronal growth, survival and differentiation. In this study we demonstrate accumulation of G(M1) in the cell-surface rafts and lysosomes of the β-gal knockout (β-gal-/-) mouse brain association with accumulation of Trk receptors and enhancement of its downstream signaling. Immunofluorescence and subcellular fractionation analysis revealed accumulation of Trk receptors in the late endosomes/lysosomes of the β-gal-/- mouse brain and their association with ubiquitin and p62. Administration of a chemical chaperone to β-gal-/- mouse expressing human mutant R201C protein resulted in a marked reduction of intracellular storage of G(M1) and phosphorylated Trk. These findings indicate that G(M1) accumulation in rafts causes activation of Trk signaling, which may participate in the pathogenesis of G(M1) -gangliosidosis.
© 2011 The Authors. Journal of Neurochemistry © 2011 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21574998     DOI: 10.1111/j.1471-4159.2011.07310.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

1.  A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.

Authors:  Tomoko Takai; Katsumi Higaki; Matilde Aguilar-Moncayo; Teresa Mena-Barragán; Yuki Hirano; Kei Yura; Liang Yu; Haruaki Ninomiya; M Isabel García-Moreno; Yasubumi Sakakibara; Kousaku Ohno; Eiji Nanba; Carmen Ortiz Mellet; José M García Fernández; Yoshiyuki Suzuki
Journal:  Mol Ther       Date:  2013-01-22       Impact factor: 11.454

Review 2.  Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.

Authors:  Olive Jung; Samarjit Patnaik; Juan Marugan; Ellen Sidransky; Wendy Westbroek
Journal:  Expert Rev Proteomics       Date:  2016-04-21       Impact factor: 3.940

3.  Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry.

Authors:  Laurent Bonesso; Monique Piraud; Céline Caruba; Emmanuel Van Obberghen; Raymond Mengual; Charlotte Hinault
Journal:  Orphanet J Rare Dis       Date:  2014-02-06       Impact factor: 4.123

Review 4.  Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases.

Authors:  Jacob M Favret; Nadav I Weinstock; M Laura Feltri; Daesung Shin
Journal:  Front Mol Biosci       Date:  2020-04-15

5.  Rapamycin promotes endothelial-mesenchymal transition during stress-induced premature senescence through the activation of autophagy.

Authors:  Norihiko Sasaki; Yoko Itakura; Masashi Toyoda
Journal:  Cell Commun Signal       Date:  2020-03-12       Impact factor: 5.712

Review 6.  Emerging novel concept of chaperone therapies for protein misfolding diseases.

Authors:  Yoshiyuki Suzuki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2014       Impact factor: 3.493

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.